To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder
Status:
Active, not recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
Overactive bladder (OAB) is a clinical condition characterized by urgency (i.e., urinary
urinary urinary urgency that is difficult to delay and unbearable) with or without urge
incontinence, usually associated with frequency and nocturia. The main drug class used is
antimuscarinics, and the clinical utility of antimuscarinic drugs is limited due to its mild
efficacy and poor tolerability due to side effects of mechanisms such as dry mouth and
constipation. In addition to poor tolerability and mild efficacy, recent literature suggests
that long-term use of anticholinergics is associated with cognitive impairment and dementia.
Therefore, the purpose of this study was to evaluate the treatment effect of overactive
bladder symptoms through the change in the average number of urination per day after
administration of JLP-2002, a beta 3-adrenergic receptor (β3-AR) agonist with an effective
alternative mechanism, for 12 weeks.